Zosano Pharma Corp (NASDAQ:ZSAN) Director Kenneth Greathouse acquired 95,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was bought at an average cost of $0.62 per share, with a total value of $58,900.00. Following the purchase, the director now owns 95,000 shares in the company, valued at $58,900. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Kenneth Greathouse also recently made the following trade(s):
- On Wednesday, November 15th, Kenneth Greathouse acquired 50,000 shares of Zosano Pharma stock. The stock was bought at an average cost of $0.62 per share, with a total value of $31,000.00.
Zosano Pharma Corp (ZSAN) opened at $0.63 on Wednesday. Zosano Pharma Corp has a 12-month low of $0.56 and a 12-month high of $3.54.
Zosano Pharma (NASDAQ:ZSAN) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.05). equities research analysts expect that Zosano Pharma Corp will post -0.79 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Zosano Pharma stock. Vanguard Group Inc. raised its holdings in Zosano Pharma Corp (NASDAQ:ZSAN) by 20.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,217,323 shares of the biotechnology company’s stock after acquiring an additional 209,251 shares during the quarter. Vanguard Group Inc. owned approximately 3.11% of Zosano Pharma worth $1,716,000 as of its most recent SEC filing. 19.68% of the stock is currently owned by hedge funds and other institutional investors.
Separately, ValuEngine raised shares of Zosano Pharma from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.